{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:08:16Z","timestamp":1792796896434,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.transci.2023.103828","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T01:21:18Z","timestamp":1696987278000},"page":"103828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Leukapheresis for CAR-T cell production and therapy"],"prefix":"10.1016","volume":"62","author":[{"given":"Ilias","family":"Pessach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.transci.2023.103828_bib1","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib2","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.transci.2023.103828_bib4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.transci.2023.103828_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib8","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102769","article-title":"Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients","volume":"59","author":"Hutt","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.transci.2023.103828_bib11","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.transci.2023.103828_bib13","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transci.2023.103828_bib14","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI0215175","article-title":"T cell homeostatic proliferation elicits effective antitumor autoimmunity","volume":"110","author":"Dummer","year":"2002","journal-title":"J Clin Investig"},{"issue":"15","key":"10.1016\/j.transci.2023.103828_bib16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.transci.2023.103828_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.transci.2023.103828_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2023.103828_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/vox.12164","article-title":"A safe therapeutic apheresis protocol in paediatric patients weighing 11 to 25 kg","volume":"107","author":"Maitta","year":"2014","journal-title":"Vox Sang"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/(SICI)1098-1101(1996)11:4<195::AID-JCA4>3.0.CO;2-6","article-title":"Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: a primer","volume":"11","author":"Gorlin","year":"1996","journal-title":"J Clin Apher"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jca.21260","article-title":"Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease","volume":"28","author":"Hunt","year":"2013","journal-title":"J Clin Apher"},{"issue":"7","key":"10.1016\/j.transci.2023.103828_bib24","first-page":"365 e1","article-title":"A clinically applicable prediction model to improve T cell collection in chimeric antigen receptor T cell therapy","volume":"28","author":"Jo","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1537-2995.2004.04210.x","article-title":"Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells","volume":"45","author":"Abrahamsen","year":"2005","journal-title":"Transfusion"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2023.103828_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/trf.14502","article-title":"Cellular collection by apheresis","volume":"58","author":"Padmanabhan","year":"2018","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jca.1017","article-title":"Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis","volume":"16","author":"Korbling","year":"2001","journal-title":"J Clin Apher"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.transci.2023.103828_bib29","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/trf.14569","article-title":"Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma","volume":"58","author":"Ceppi","year":"2018","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/trf.14365","article-title":"Cord blood-derived T cells allow the generation of a more naive tumor-reactive cytotoxic T-cell phenotype","volume":"58","author":"Kwoczek","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2023.103828_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21037\/sci.2019.09.01","article-title":"Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood","volume":"6","author":"Lin","year":"2019","journal-title":"Stem Cell Invest"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000528331","article-title":"Get off on the right foot: how to plan an efficient leukocytapheresis to collect T cells for CAR T-cell manufacturing","volume":"50","author":"Pineyroa","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.transci.2023.103828_bib34","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","article-title":"Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics","volume":"27","author":"Panch","year":"2019","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.transci.2023.103828_bib35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jcyt.2019.10.005","article-title":"Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture","volume":"21","author":"Tyagarajan","year":"2019","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.17121","article-title":"Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed\/refractory large B-cell lymphoma","volume":"192","author":"Lutfi","year":"2021","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.transci.2023.103828_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184664","article-title":"CAR-T after stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies","volume":"13","author":"Bartolo-Ibars","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tmrv.2016.03.001","article-title":"CAR-T cell therapies from the transfusion medicine perspective","volume":"30","author":"Fesnak","year":"2016","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2023.103828_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cryobiol.2018.06.007","article-title":"Effects of cryopreservation on chimeric antigen receptor T cell functions","volume":"83","author":"Xu","year":"2018","journal-title":"Cryobiology"},{"issue":"10","key":"10.1016\/j.transci.2023.103828_bib40","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcyt.2016.06.014","article-title":"Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products","volume":"18","author":"Berens","year":"2016","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/trf.12428","article-title":"Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation","volume":"54","author":"Fisher","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jca.21618","article-title":"Comparison of the CMNC and MNC apheresis protocol for the collection of T-cells showed comparable outcome: an observational study in a single centre","volume":"33","author":"Putensen","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103828_bib43","doi-asserted-by":"crossref","first-page":"1024362","DOI":"10.3389\/fonc.2022.1024362","article-title":"Impact of cryopreservation on CAR T production and clinical response","volume":"12","author":"Brezinger-Dayan","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib44","doi-asserted-by":"crossref","first-page":"18696","DOI":"10.1038\/s41598-022-23589-9","article-title":"T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy","volume":"12","author":"Wada","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","article-title":"Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium","volume":"7","author":"Stefanski","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.transci.2023.103828_bib46","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.transci.2023.103828_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1189\/jlb.2RI0317-097R","article-title":"Transcriptional and epigenetic regulation of T cell hyporesponsiveness","volume":"102","author":"Pereira","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"9","key":"10.1016\/j.transci.2023.103828_bib49","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1084\/jem.187.9.1383","article-title":"Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes","volume":"187","author":"Gallimore","year":"1998","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.transci.2023.103828_bib50","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib51","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"issue":"17","key":"10.1016\/j.transci.2023.103828_bib52","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.transci.2023.103828_bib54","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10.1016\/j.transci.2023.103828_bib55","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.transci.2023.103828_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071140","article-title":"Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell malignancies","volume":"11","author":"Beider","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2023.103828_bib59","first-page":"1","article-title":"Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed\/refractory follicular lymphoma","author":"Fried","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib60","first-page":"251","article-title":"Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma","volume":"28","author":"Kedmi","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000148","article-title":"Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients","volume":"8","author":"Itzhaki","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib63","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0b013e318209c94c","article-title":"Establishment and large-scale expansion of minimally cultured \"young\" tumor infiltrating lymphocytes for adoptive transfer therapy","volume":"34","author":"Itzhaki","year":"2011","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib64","first-page":"170","article-title":"Second-line treatment with CAR T-cell therapy for large B-cell lymphoma","volume":"21","author":"Lutfi","year":"2023","journal-title":"Clin Adv Hematol Oncol"},{"issue":"18","key":"10.1016\/j.transci.2023.103828_bib65","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib66","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.transci.2016.10.004","article-title":"Comparison of Spectra Optia and COBE Spectra apheresis systems' performances for red blood cell exchange procedures","volume":"55","author":"Kim","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051225","article-title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL","volume":"9","author":"Korell","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.transci.2023.103828_bib68","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/543531","article-title":"DNA damage induced by alkylating agents and repair pathways","volume":"2010","author":"Kondo","year":"2010","journal-title":"J Nucleic Acids"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026644","article-title":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I\/II clinical trial protocol","volume":"9","author":"Schubert","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib70","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib71","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib72","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pule","year":"2005","journal-title":"Mol Ther"},{"issue":"17","key":"10.1016\/j.transci.2023.103828_bib73","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.transci.2023.103828_bib75","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib77","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428190701742506","article-title":"B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period","volume":"49","author":"Lim","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib78","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pr"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib79","first-page":"375","article-title":"The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma","volume":"16","author":"Lulla","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib80","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.transci.2023.103828_bib81","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/trf.17030","article-title":"Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients","volume":"62","author":"Harrer","year":"2022","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.transci.2023.103828_bib82","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib83","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.transci.2023.103828_bib84","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.transci.2023.103828_bib85","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.transci.2023.103828_bib86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib88","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/hon.2975","article-title":"Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: a single-center, retrospective, cohort study","volume":"40","author":"Wang","year":"2022","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.transci.2023.103828_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005145","article-title":"Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.transci.2023.103828_bib90","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.transci.2023.103828_bib91","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.transci.2023.103828_bib92","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.transci.2023.103828_bib94","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.transci.2023.103828_bib95","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.transci.2023.103828_bib96","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.transci.2023.103828_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib98","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"issue":"22","key":"10.1016\/j.transci.2023.103828_bib99","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.transci.2023.103828_bib101","doi-asserted-by":"crossref","first-page":"1079181","DOI":"10.3389\/fimmu.2022.1079181","article-title":"Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib102","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1017\/S147895151600095X","article-title":"Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia","volume":"15","author":"Prudent","year":"2017","journal-title":"Palliat Support Care"},{"key":"10.1016\/j.transci.2023.103828_bib103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.transci.2023.103828_bib104","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103828_bib105","doi-asserted-by":"crossref","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"issue":"37","key":"10.1016\/j.transci.2023.103828_bib106","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1039\/D2TB00592A","article-title":"Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy","volume":"10","author":"Balagopal","year":"2022","journal-title":"J Mater Chem B"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib107","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021045","article-title":"Do CAR-T and allogeneic stem cell transplant both have a place in lymphoid neoplasms","volume":"24","author":"Martino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.transci.2023.103828_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Martinez Bedoya","year":"2021","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.transci.2023.103828_bib110","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1182\/bloodadvances.2022009397","article-title":"CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products","volume":"7","author":"Kath","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.transci.2023.103828_bib111","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2018-99-117910","article-title":"Comparison of chimeric antigen receptor T cells from allogenic or autologous sources in patients with acute lymphoblastic leukemia","volume":"132","author":"Hu","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib112","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2023.103828_bib113","article-title":"Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.transci.2023.103828_bib114","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2023.103828_bib115","doi-asserted-by":"crossref","first-page":"1191382","DOI":"10.3389\/fimmu.2023.1191382","article-title":"Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.transci.2023.103828_bib116","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2008.11.029","article-title":"Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies","volume":"15","author":"Chen","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9967","key":"10.1016\/j.transci.2023.103828_bib117","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"177","key":"10.1016\/j.transci.2023.103828_bib118","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"224","key":"10.1016\/j.transci.2023.103828_bib119","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.transci.2023.103828_bib120","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.transci.2023.103828_bib121","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.transci.2023.103828_bib122","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an Anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.transci.2023.103828_bib123","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.transci.2023.103828_bib124","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-t therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib126","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.transci.2023.103828_bib127","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","article-title":"Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies","volume":"18","author":"Sheppard","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib129","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.transci.2023.103828_bib130","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103828_bib131","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharm"},{"issue":"10266","key":"10.1016\/j.transci.2023.103828_bib132","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.transci.2023.103828_bib133","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib134","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/bjh.18105","article-title":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","volume":"197","author":"Jacoby","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.transci.2023.103828_bib135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2023.103828_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.834113","article-title":"Effectiveness and safety of anti-CD19 chimeric antigen receptor-T cell immunotherapy in patients with relapsed\/refractory large B-cell lymphoma: a systematic review and meta-analysis","volume":"13","author":"Ying","year":"2022","journal-title":"Front Pharm"},{"key":"10.1016\/j.transci.2023.103828_bib137","article-title":"Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.transci.2023.103828_bib139","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","article-title":"Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"30","author":"Elsallab","year":"2023","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.transci.2023.103828_bib140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.transci.2023.103828_bib141","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.transci.2023.103828_bib142","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transpl"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223002434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223002434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:56:01Z","timestamp":1761468961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223002434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":142,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1473050223002434"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103828","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukapheresis for CAR-T cell production and therapy","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103828"}}